NasdaqCM:TGTXBiotechs
TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings
TG Therapeutics (NasdaqCM:TGTX) experienced a notable price increase of 24% over the last quarter, which aligns with positive developments regarding its product, BRIUMVI, at a prestigious medical conference. The favorable reception and strong earnings results, transitioning from a loss to profitability, alongside clear corporate revenue guidance, likely bolstered investor confidence. Despite a generally volatile market, TG Therapeutics’ share buyback program and projection of substantial...